The renal effects of droxidopa are maintained in propranolol treated cirrhotic rats

Liver International

Volumn 35, Issue 2, 2015, Pages 326-334

  Rodríguez, Sarai ^a   Raurell, Imma ^a   Ezkurdia, Nahia ^a   Augustin, Salvador ^a   Esteban, Rafael ^a,b   Genescà, Joan ^a,b   Martell, María ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Cirrhosis; Hepatorenal syndrome; Hyperdynamic syndrome; Non selective beta blockers; Portal hypertension; Pro adrenergic drug; Statins

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ATORVASTATIN; BILIRUBIN; CARBON TETRACHLORIDE; CARVEDILOL; CREATININE; DROXIDOPA; POTASSIUM; PROPRANOLOL; SERUM ALBUMIN; SODIUM; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; HEPTANOIC ACID DERIVATIVE; PROPANOLAMINE DERIVATIVE; PYRROLE DERIVATIVE;

ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT LIGATION; BILIRUBIN BLOOD LEVEL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIURESIS; DRUG EFFECT; EXPERIMENTAL LIVER CIRRHOSIS; FREE WATER CLEARANCE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PORTAL VEIN BLOOD PRESSURE; POTASSIUM BLOOD LEVEL; RAT; SERUM OSMOLALITY; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; SODIUM EXCRETION; SUPERIOR MESENTERIC ARTERY; SUPERIOR MESENTERIC ARTERY RESISTANCE; TREATMENT DURATION; URINALYSIS; URINE FLOW RATE; URINE OSMOLALITY; URINE VOLUME; ANIMAL; BLOOD; DRUG COMBINATION; DRUG EFFECTS; DRUG SCREENING; HEMODYNAMICS; LIVER CIRRHOSIS, EXPERIMENTAL; OSMOLARITY; PROCEDURES; URINE; VASCULAR RESISTANCE;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BILIRUBIN; CARBAZOLES; CREATININE; DROXIDOPA; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; HEMODYNAMICS; HEPTANOIC ACIDS; LIVER CIRRHOSIS, EXPERIMENTAL; MESENTERIC ARTERY, SUPERIOR; OSMOLAR CONCENTRATION; PORTAL PRESSURE; POTASSIUM; PROPANOLAMINES; PROPRANOLOL; PYRROLES; RATS; SERUM ALBUMIN; SODIUM; VASCULAR RESISTANCE;

EID: 84921599949     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12472     Document Type: Article

References (30)

1. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-7.
2. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006; 43: S121-31.
3. Bosch J, Berzigotti A, Garcia-Pagan JC, Abraldes JG. The management of portal hypertension: rational basis, available treatments and future options. J Hepatol 2008; 48: S68-92.
4. Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009; 361: 1279-90.
5. Martell M, Coll M, Ezkurdia N, Raurell I, Genesca J. Physiopathology of splanchnic vasodilation in portal hypertension. World J Hepatol 2010; 2: 208-20.
6. Coll M, Genesca J, Raurell I, et al. Down-regulation of genes related to the adrenergic system may contribute to splanchnic vasodilation in rat portal hypertension. J Hepatol 2008; 49: 43-51.
7. Coll M, Martell M, Raurell I, et al. Atrophy of mesenteric sympathetic innervation may contribute to splanchnic vasodilation in rat portal hypertension. Liver International 2010; 30: 593-602.
8. Ezkurdia N, Coll M, Raurell I, et al. Blockage of the afferent sensitive pathway prevents sympathetic atrophy and hemodynamic alterations in rat portal hypertension. Liver International 2012; 32: 1295-305.
9. Ezkurdia N, Raurell I, Rodriguez S, et al. Inhibition of neuronal apoptosis and axonal regression ameliorates sympathetic atrophy and hemodynamic alterations in portal hypertensive rats. PLoS One 2014; 9: e84374.
10. Coll M, Rodriguez S, Raurell I, et al. Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats. Hepatology 2012; 56: 1849-60.
11. De Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53: 762-8.
12. Lebrec D. Pharmacological treatment of portal-hypertension - hemodynamic-effects and prevention of bleeding. Pharmacol Ther 1994; 61: 65-107.
13. Banares R, Moitinho E, Piqueras B, et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha(1)-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology 1999; 30: 79-83.
14. Bosch J. Carvedilol for portal hypertension in patients with cirrhosis. Hepatology 2010; 51: 2214-8.
15. Feuerstein GZ, Ruffolo RR. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Eur Heart J 1996; 17: 24-9.
16. Kurum T, Tatli E, Yuksel M. Effects of carvedilol on plasma levels of pro-inflammatory cytokines - in patients with ischemic and nonischemic dilated cardiomyopathy. Tex Heart Inst J 2007; 34: 52-9.
17. Zafra C, Abraldes JG, Turnes J, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004; 126: 749-55.
18. Abraldes JG, Rodriguez-Vilarrupla A, Graupera M, et al. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol 2007; 46: 1040-6.
19. Abraldes JG, Albillos A, Banares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009; 136: 1651-8.
20. Moreno M, Ramalho LN, Sancho-Bru P, et al. Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. Am J Physiol-Gastrointest Liver Physiol 2009; 296: G147-56.
21. Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med 2001; 5: 378-87.
22. Trebicka J, Hennenberg M, Laleman W, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007; 46: 242-53.
23. Trebicka J, Hennenberg M, Odenthal M, et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol 2010; 53: 702-12.
24. Beck PL, Lee SS. Vitamin-k-1 improves survival in bile-duct-ligated rats with cirrhosis. J Hepatol 1995; 23: 235.
25. Claria J, Jimenez W. Renal Dysfunction and Ascites in Carbon Tetrachloride-Induced Cirrhosis in Rats. In: Arroyo V, Gines P, Rodes J, Schrier RW, eds. Ascites and Renal Dysfunction in The Liver Disease. Pathogenesis, Diagnosis and Treatment, Melden, MA: Blackwell Science, 1999; 379-96.
26. Stanley AJ, Therapondos G, Helmy A, Hayes PC. Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. J Hepatol 1999; 30: 479-84.
27. Buhler FR, Brunner HR, Baer L, Vaughan ED, Laragh JH. Propranolol inhibition of renin secretion - specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med 1972; 287: 1209-14.
28. Wilkinson SP, Bernardi M, Smith IK, et al. Effect of beta-adrenergic blocking-drugs on reninaldosterone system, sodium excretion, and renal hemodynamics in cirrhosis with ascites. Gastroenterology 1977; 73: 659-63.
29. Vilas-Boas WW, Ribeiro-Oliveira A, Ribeiro RD, et al. Effect of propranolol on the splanchnic and peripheral renin angiotensin system in cirrhotic patients. World J Gastroenterol 2008; 14: 6824-30.
30. Rector WG, Reynolds TB. Propranolol in the treatment of cirrhotic ascites. Arch Intern Med 1984; 144: 1761-3.